Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

1. Delforge, M.
2. Patel, K.
3. Eliason, L.
4. Dhanda, D.
5. Shi, L.
6. Guo, S.
7. Marshall, T.S.
8. Arnulf, B.
9. Cavo, M.
10. Nooka, A.
11. Manier, S.
12. Callander, N.
13. Giralt, S.
14. Einsele, H.
15. Ailawadhi, S.
16. Popa McKiver, M.
17. Cook, M.
18. Rodríguez-Otero, P.